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Purpose of the Study: Ventricular arrhythmias (VA), atypical ﬂutter and/or conduction disorders may be life-
threatening manifestations of Cardiac Sarcoidosis (CS), whose etiologic assessment represents a challenge encom-
passing biological and histological ﬁndings as well as imaging biomarkers. Considering the frequent virus-nega-
tivity, autoreactive immunopathogenesis besides CS may cause a progressive arrhythmogenic cardiac ﬁbrosis
whose clinical presentation remains poorly deﬁned.
Methods: We report a series of 21 consecutive pts (57 + 13.4 y, n ¼ 4 females) addressed at our tertiary uni-
versity center because of VA, atypical ﬂutter and/or conduction disorders, who underwent a comprehensive diag-
nostic work-up including coronary angiography (CA) and Cardiac Magnetic Resonance (CMR) in those without
an ICD. 18F-FDG PET scan (PET) was performed in pts with normal CA and evidence for delayed enhancement
(DE) within the left ventricle (LV) at CMR. Pts displaying focal hypermetabolic activity at PET underwent direc-
ted cardiac biopsies and an extensive blood testing searching for autoimmunity and viral serologies.
Summary: DE within the LV was observed in 18 pts with normal CA and no contraindication for CMR. A DE
within the interventricular septum suggestive of CS was reported in 11 (52%) pts only. A PET, performed in 21
pts, revealed a hypermetabolic LV activity in 20 pts (95%) of whom four (19%) displayed a focal hypermetabolic
right ventricle activity as well. The ﬁgure below illustrates an example of septal and lateral DE at CMR (A) and
focal hypermetabolic LV activity at PET (B). Laboratory tests were not contributive except for three (14%) posi-
tive Tuberculosis spots indicating latent infection. Directed myocardial biopsies, performed in 19 pts, were abnor-
mal in 14 (74%) cases consisting in two (14%) CS only and two (14%) lymphocyte myocarditis. The 10
remaining pts showed ﬁbrosis. Despite the lack of criteria fulﬁlling the diagnosis of CS, immunosuppressive treat-
ment has been introduced in 14 (67%) pts up to now, resulting in complete suppression of focal hypermetabolic
activity in nine (64%) pts and a partial reduction in the remaining ﬁve (36%) ones (Figure C).
Conclusions: A multi-modality assessment based on CMR and FDG-PET allowed the detection of a new focal
hypermetabolic syndrome sharing several features with CS including a favorable response to immunosuppressive
treatment. In contrast to CS, there are no biological markers indicative of systemic inﬂammation.
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Purpose of the study: Cardiac resynchronization therapy (CRT) was proved to be effective in patients
with heart failure and left bundle branch block (LBBB). Recently, new ECG criteria have been proposed
for the diagnosis of LBBB. These criteria are stricter than the current American Heart Association
(AHA) criteria and thus increase the speciﬁcity of LBBB diagnosis. We assessed the rate of echocardio-
graphic response to CRT in patients who did and did not meet new criteria (Strict-LBBB).
Method used: Consecutive patients who received CRT deﬁbrillators were enrolled in the CRT MORE
registry. Patients with no-LBBB QRS morphology according to AHA, atrial ﬁbrillation, right bundle
branch block and right ventricular pacing were excluded from the analysis. Strict-LBBB was deﬁned as:
QRS 140ms for men and 130ms for women, QS or rS in V1–V2, mid-QRS notching or slurring in
2 contiguous leads. Patients showing a relative decrease of 15% in left ventricular end systolic
volume (LVESV) at 12 months were deﬁned as responders.
Summary of results: Among 335 patients with AHA LBBB, 131 (39%) had Strict-LBBB. Patients
with and without Strict-LBBB showed comparable baseline characteristics except for QRS duration
(166 + 20ms vs 152 + 25ms, p , 0.001). At 12-month evaluation responders were 205 (61%). 85
(65%) patients had Strict-LBBB and 120 (59%) had no Strict-LBBB (p ¼ 0.267). On multivariate ana-
lysis, history of atrial ﬁbrillation, larger LVESV, and presence of mid-QRS notching in 1 lead (OR
1.96; 95%CI 1.04 to 3.70, p ¼ 0.038) were independently associated with the echocardiographic re-
sponse.
Conclusion: Recently proposed stricter criteria for LBBB diagnosis did not improve the identiﬁcation
of CRT responders. Among ECG variables, only the presence of mid-QRS notching in 1 lead was
associated with the echocardiographic response.
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Masih Maﬁ Rad, Elien Engels, Yuri Blaauw, Justin Luermans, Laurent Pison, Harry J. Crijns, Frits Prinzen,
and Kevin Vernooy
Maastricht, Netherlands
Introduction: Delayed left ventricular lateral wall (LVLW) activation is considered the electrical substrate under-
lying LV dysfunction amenable to cardiac resynchronization therapy (CRT). The purpose of this study was to
assess LVLW activation in CRT candidates using coronary venous electroanatomic mapping (EAM) and to inves-
tigate whether the QRS area (QRSAREA) on the vectorcardiogram (VCG) can identify delayed LVLW activation.
Methods: 51 consecutive CRT candidates (29 LBBB, 15 IVCD, 7 RBBB) underwent intraprocedural coronary
venous EAM using EnSite NavX. VCGs were constructed from preprocedural digital 12-lead ECGs using the
Kors method. QRSAREAwas assessed and compared to QRS duration and 5 different LBBB deﬁnitions.
Results: Delayed LVLW activation (activation time .75% of QRS duration, example in ﬁgure) occurred in 38 of
51 patients (29/29 LBBB, 8/15 IVCD, 1/7 RBBB). QRSAREA was larger in patients with than in patients
without delayed LVLW activation (108 + 42 mVs vs 51 + 27 mVs, P , .001), and identiﬁed delayed LVLW
activation better than QRS duration (area under the curve 0.89 [95% conﬁdence interval 0.79-0.99] vs 0.49 [95%
conﬁdence interval 0.33-0.65] ). QRSAREA .69 mVs diagnosed delayed LVLW activation with a higher sum of
sensitivity (87%) and speciﬁcity (92%) than any of the LBBB deﬁnitions. Of the different LBBB deﬁnitions, the
European Society of Cardiology textbook deﬁnition performed best with sensitivity of 76% and speciﬁcity of
100%.
Conclusion: Coronary venous EAM can be used during CRT implantation to determine the presence of delayed
LVLW activation. QRSAREA is a noninvasive alternative for intracardiac measurements of electrical activation,
which identiﬁes delayed LVLW activation better than QRS duration and LBBB morphology.
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Purpose: Multisite biventricular (BiV) pacing may offer additional acute hemodynamic beneﬁts to traditional
BiV pacing either through multivein pacing (MVP) or multipolar pacing (MPP) with a multielectrode left ven-
tricular (LV) lead within one vein.
Our objective was to test whether the presence, amount and distribution of scar impacts the degree of acute
hemodynamic response (AHR) with multisite pacing.
Method: Multi-center study, where patients underwent an acute hemodynamic study as part of their BiV proced-
ure. LV dP/dtmax was measured to determine % change from baseline pacing (AAI) compared to ‘optimal’ BiV
pacing, MPP and MVP in the same patients. All patients had late gadolinium enhanced CMR imaging to assess
for scar burden and distribution.
Summary of Results: Twenty-four LBBB patients completed the study (83% male; QRS width 171 þ/- 20 ms;
38%/62% NYHA class II/III; and 58% ischemic). Scar volume was 6.0 + 7.0% with 6/24 patients having a
scar volume.8.48%. MPP and MVP displayed similar AHR when compared to best BiV site (BBV). There was a
statistically signiﬁcant correlation between the difference in AHR (MPP-BBV) versus scar volume (R ¼ 0.49, p
¼ 0.02), however the mean AHR beneﬁt gained was only 3.9 + 5.3% for MPP in those that improved. There
was no correlation between MVP AHR improvement over BBV and scar volume (R ¼ 0.111, p ¼ 0.62). Scar
volume of 8.48% predicted an improvement in AHR with MPP (sensitivity 83% speciﬁcity 94%); this was not the
case with MVP pacing (ﬁgure 1). The presence of the multielectrode lead in scar also predicted MPP AHR im-
provement (p ¼ 0.04). The presence of either MV lead in scar did not predict MVP AHR improvement.
Conclusion: Greater scar volume and the distribution of scar at the pacing site may increase the likelihood of
AHR improvement with MPP but not MVP over BBV.
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